<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The presence of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific DNA methylation patterns in epithelial colorectal cells in human feces provides the prospect of a simple, non-invasive screening test for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and its precursor, the <z:mpath ids='MPATH_270'>adenoma</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>This study investigates a panel of epigenetic markers for the detection of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and <z:mpath ids='MPATH_270'>adenomas</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Candidate biomarkers were subjected to quantitative methylation analysis in test sets of tissue samples from <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e>, <z:mpath ids='MPATH_270'>adenomas</z:mpath>, and <z:mpath ids='MPATH_458'>normal</z:mpath> colonic mucosa </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> findings were verified in independent clinical validation series </plain></SENT>
<SENT sid="4" pm="."><plain>A total of 523 human samples were included in the study </plain></SENT>
<SENT sid="5" pm="."><plain>Receiver operating characteristic (ROC) curve analysis was used to evaluate the performance of the biomarker panel </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Promoter hypermethylation of the genes CNRIP1, FBN1, INA, MAL, SNCA, and SPG20 was frequent in both <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> (65-94%) and <z:mpath ids='MPATH_270'>adenomas</z:mpath> (35-91%), whereas <z:mpath ids='MPATH_458'>normal</z:mpath> mucosa samples were rarely (0-5%) methylated </plain></SENT>
<SENT sid="7" pm="."><plain>The combined sensitivity of at least two positives among the six markers was 94% for <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> and 93% for <z:mpath ids='MPATH_270'>adenoma</z:mpath> samples, with a specificity of 98% </plain></SENT>
<SENT sid="8" pm="."><plain>The resulting areas under the ROC curve were 0.984 for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> and 0.968 for <z:mpath ids='MPATH_270'>adenomas</z:mpath> versus <z:mpath ids='MPATH_458'>normal</z:mpath> mucosa </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: The novel epigenetic marker panel shows very high sensitivity and specificity for both <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> and <z:mpath ids='MPATH_270'>adenomas</z:mpath> </plain></SENT>
<SENT sid="10" pm="."><plain>Our findings suggest this biomarker panel to be highly suitable for early <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> detection </plain></SENT>
</text></document>